Rep. Gilbert Ray Cisneros, Jr. Buys Veracyte, Inc. (NASDAQ:VCYT) Stock

Posted by Stacy Sanders on Apr 10th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Veracyte, Inc. (NASDAQ:VCYT). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Veracyte stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Veracyte Trading Down 0.8%

Shares of Veracyte stock traded down $0.26 during trading on Friday, hitting $31.09. 798,487 shares of the stock were exchanged, compared to its average volume of 898,922. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of 37.46 and a beta of 1.96. The company has a fifty day moving average price of $34.19 and a 200-day moving average price of $38.23. Veracyte, Inc. has a 1-year low of $22.61 and a 1-year high of $50.71.

Veracyte (NASDAQ:VCYT – Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.12. The company had revenue of $140.64 million for the quarter, compared to analyst estimates of $135.79 million. Veracyte had a net margin of 12.83% and a return on equity of 8.05%. Veracyte’s revenue for the quarter was up 18.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 EPS. Equities research analysts forecast that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.

Insider Buying and Selling at Veracyte

In other Veracyte news, insider John Leite sold 5,260 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $35.19, for a total value of $185,099.40. Following the completion of the sale, the insider owned 107,580 shares of the company’s stock, valued at $3,785,740.20. The trade was a 4.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Rebecca Chambers sold 18,341 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $36.14, for a total transaction of $662,843.74. Following the completion of the sale, the chief financial officer directly owned 131,196 shares of the company’s stock, valued at $4,741,423.44. This represents a 12.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 75,782 shares of company stock worth $2,722,097. 1.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on VCYT shares. Morgan Stanley lowered their price objective on shares of Veracyte from $48.00 to $37.00 and set an “underweight” rating on the stock in a research note on Thursday, March 5th. UBS Group restated a “buy” rating on shares of Veracyte in a research note on Monday, January 12th. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Veracyte in a research note on Wednesday, April 1st. Wall Street Zen upgraded shares of Veracyte from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Guggenheim decreased their price target on shares of Veracyte from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $44.20.

Get Our Latest Report on Veracyte

Institutional Trading of Veracyte

Institutional investors have recently bought and sold shares of the business. Torren Management LLC bought a new stake in Veracyte in the 4th quarter valued at about $37,000. First Horizon Corp bought a new stake in Veracyte in the 3rd quarter valued at about $31,000. Empowered Funds LLC bought a new stake in Veracyte in the 4th quarter valued at about $42,000. Smartleaf Asset Management LLC boosted its holdings in Veracyte by 159.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 679 shares during the period. Finally, Osaic Holdings Inc. boosted its holdings in Veracyte by 289.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 893 shares during the period.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Veracyte

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.